e-Therapeutics plc Appointment of Director (1796V)
01 November 2017 - 6:00PM
UK Regulatory
TIDMETX
RNS Number : 1796V
e-Therapeutics plc
01 November 2017
e-Therapeutics
('e-Therapeutics' or the 'Company')
Appointment of Director
Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a
company pioneering the use of Network-Driven Drug Discovery (NDD)
to create new and better drugs, announces the appointment of
Christine Soden as non-executive director, and the retirement of
Brad Hoy who has served on the e-Therapeutics Board as a
non-executive director for nine years. Christine will take over
from Brad Hoy as Chair of the Board's Audit & Risk
Committee.
Christine Soden BSc, ACA qualified with Price Waterhouse and has
extensive financial management experience in the healthcare
industry, having been Group Financial Controller at Medeva plc
before serving as CFO in several public healthcare companies
including Optos plc, BTG plc, and Celltech Chiroscience plc.
Currently Christine is CFO at Acacia Pharma Group Limited and is a
non-executive director at two private biotech companies.
Iain Ross, Chairman of e-Therapeutics commented: "We are
delighted to be able to welcome Christine to the Board of
e-Therapeutics plc. She brings a wealth of relevant experience as
we look to build the Company going forward. I would also like to
thank Brad Hoy on behalf of the Company for his service and
commitment over the last nine years and also to personally thank
him for his support during my tenure as Chairman."
The following additional information is provided in accordance
with Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for
Companies.
Christine Helen Soden, aged 60, has no shareholding in
e-Therapeutics plc. Her current and previous directorships or
partnerships are detailed below:
Current directorships and partnerships:
Acacia Pharma Group Limited
Acacia Pharma Limited
Fertility Focus Limited
Futurenova Limited
Past directorships and partnerships held within the last 5
years:
CT2 Holdings Limited
CT2 Limited
Electrical Geodesics, Inc.
There is no further information to be disclosed pursuant to
Schedule Two, paragraph (g) of the AIM Rules for Companies.
-Ends-
For further information, please contact:
e-Therapeutics plc Tel: +44 (0) 1993
Iain Ross, Chairman 883 125
Ray Barlow, CEO www.etherapeutics.co.uk
Steve Medlicott, CFO
Numis Securities Limited Tel: +44 (0) 207
Michael Meade/Freddie 260 1000
Barnfield www.numis.com
(Nominated Adviser)
James Black (Corporate
Broking)
Instinctif Partners Tel: +44 (0) 207
Melanie Toyne Sewell/Alex 457 2020
Shaw Email: e-Therapeutics@instinctif.com
Notes to Editors
About e-Therapeutics plc
e-Therapeutics is an Oxford-based company with a unique and
powerful computer-based drug discovery platform and a specialised
approach to network biology.
Its novel methodology and Discovery Engine allow the Company to
discover new and better drugs in a more efficient and effective
way.
For more information about the Company, please visit
www.etherapeutics.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUASURBNAROUA
(END) Dow Jones Newswires
November 01, 2017 03:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024